Verastem Oncology's VS-7375 receives FDA fast track designation, offering hope for targeted treatment in KRAS G12D-mutated ...

A recent study characterized the expression of ADC targets across ovarian cancer histotypes. Findings suggest ...

Mariam Eskander, MD, explores how food insecurity and geographic barriers hinder breast cancer trial participation, ...

An expert discusses how optimal sequencing of therapies remains unclear in lower-risk MDS, with emerging combination ...

An expert discusses how real-world evidence and patient-reported outcomes support luspatercept’s clinical benefits, while ...

The EU approves belantamab mafodotin combinations, enhancing treatment options for relapsed multiple myeloma patients with ...

During a live event, Bruna Pellini, MD, discussed the efficacy of cemiplimab in PD-L1-high non–small cell lung cancer.

Botensilimab/balstilimab (BOT/BAL) synergistically activate and sustain immune attack, offering a promising new strategy for ...

Patritumab deruxtecan shows promising survival rates and manageable safety in treating leptomeningeal metastatic disease, ...

During a live event, Mark Yarchoan, MD, and participants reviewed adverse event management for 3 different combination ...